PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance

REFERENCES

• Vanhaesebroeck B., Waterfield M. D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239–254
   PubMed Web of Science ®Google Scholar
• Brunet A., Bonni A., Zigmond M. J., Lin M. Z., Juo P., Hu L. S., Anderson M. J., Arden K. C., Blenis J., Greenberg M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–868
   PubMed Web of Science ®Google Scholar
• Aoki M., Blazek E., Vogt P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001; 98: 136–141
   PubMed Web of Science ®Google Scholar
• Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S. M., Riggins G. J., Willson J. K., Markowitz S., Kinzler K. W., Vogelstein B., Velculescu V. E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554
   PubMed Web of Science ®Google Scholar
• Schonleben F., Ciau N. T., Ho D. J., Li X., Allendorf J. D., Remotti H. E., Su G. H. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006; 12: 3851–3855
   PubMed Web of Science ®Google Scholar
• Lee J. W., Soung Y. H., Kim S. Y., Lee H. W., Park W. S., Nam S. W., Kim S. H., Lee J. Y., Yoo N. J., Lee S. H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477–1480
   PubMed Web of Science ®Google Scholar
• Levine D. A., Bogomolniy F., Yee C. J., Lash A., Barakat R. R., Borgen P. I., Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11: 2875–2878
   PubMed Web of Science ®Google Scholar
• Wang Y., Helland A., Holm R., Kristensen G. B., Borresen-Dale A-L. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005; 25(3)322
   PubMedGoogle Scholar
• Oda K., Stokoe D., Taketani Y., McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65(23)10669–10673
   PubMed Web of Science ®Google Scholar
• Garcia-Rostan G., Costa A. M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M. J., Herrero A., Fusco A., Cameselle-Teijeiro J., Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005; 65: 10199–10207
   PubMed Web of Science ®Google Scholar
• López-Knowles E., Hernández S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardón A., Serra C. F. X. Real and EPICURO Study Group Investigators. PIK3CA Mutations Are an Early Genetic Alterations Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors. Cancer Res 2006; 66: 7401–7404
   PubMed Web of Science ®Google Scholar
• Kawano O., Sasaki H., Endo K., Suzuki E., Haneda H., Yukiue H., Kobayashi Y., Yano M., Fujii Y. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54(2)209–215
   PubMed Web of Science ®Google Scholar
• Kang S., Bader A. G., Vogt P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005; 102(3)802–807
   PubMed Web of Science ®Google Scholar
• Samuels Y., Diaz L., Jr., Schmidt-Kittler O., Cummins J. M., DeLong L., Cheong I., Rago C., Huso D. L., Lengauer C., Kinzler K. W., Vogelstein B., Velculescu V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561–573
   PubMed Web of Science ®Google Scholar
• Guo X. N., Rajput A., Rose R., Hauser J., Beko A., Kuropatwinski K., LeVea C., Hoffman R. M., Brattain M. G., Wang J. Mutant PIK3CA-bearing colon cancer cell display increased metastasis in an orthotopic model. Cancer Res 2007; 67: 5851–5858
   PubMed Web of Science ®Google Scholar
• Bachman K. E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B. G., Lin C., Peters B. A., Velculescu V. E., Park B. K. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772–775
   PubMed Web of Science ®Google Scholar
• Wu G., Xing M., Mambo E., Huang X., Liu J., Guo Z., Chatterjee A., Goldenberg D., Gollin S. M., Sukumar S., Trink B., Sidransky D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7(5)609–616
   Google Scholar
• Campbell I. G., Russell S. E., Choong D. Y., Montgomery K. G., Ciavarella M. L., Hooi C. S., Cristiano B. E., Pearson R. B., Phillips W. A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64(21)7678–7681
   PubMed Web of Science ®Google Scholar
• Reed E., Yu J. J., Davies A., Gannon J., Armentrout S. L. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003; 9: 5299–5305
   PubMed Web of Science ®Google Scholar
• Quinn J. E., Kennedy R. D., Mullan P. B., Gilmore P. M., Carty M., Johnston P. G., Harkin D. P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221–6228
   PubMed Web of Science ®Google Scholar
• Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M. L., Goel A., Barbieri V., Costanzo F., Boland C. R., Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285–1291
   PubMed Web of Science ®Google Scholar
• Saal L. H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J. S., Malmstrom P. O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65(7)2554–2559
   PubMed Web of Science ®Google Scholar
• Pérez-Tenorio G., Alkhori L., Olsson B., Waltersson M. A., Nordenskjöld B., Rutqvist L. E., Skoog L., Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13: 3577–3584
   PubMed Web of Science ®Google Scholar
• Maruyama N., Miyoshi Y., Taguchi T., Tamaki Y., Monden M., Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007; 13: 408–414
   PubMed Web of Science ®Google Scholar
• Li S. Y., Rong M., Grieu F., Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006; 96(1)91–95
   PubMed Web of Science ®Google Scholar
• Quinn J. E., James C. R., Stewart G. E., Mulligan J. M., White P., Chang K. F., Mullan P. B., Johnston P. G., Wilson R. H., Harkin D. P. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13(24)7413–7420
   Google Scholar
• Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Sanchez-Ronco M., Queralt C., Majo J., Sanchez J. M., Sanchez J. J., Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics 2004; 13(20)2443–2449
   PubMed Web of Science ®Google Scholar
• Hayes D. F., Thor A. D., Dressler L. G., Weaver D., Edgerton S., Cowan D., Broadwater G., Goldstein L. J., Martino S., Ingle J. N., Henderson C., Norton L., Winer E. P., Hudis C. A., Ellis M. J., Berry D. A., for the Cancer and Leukemia Group B. (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496–1506
   PubMed Web of Science ®Google Scholar
• Zhang L., Yang N., Liang S., Barchetti A., Vezzani C., Huang J., O'Brien-Jenkins A., Rubin S. C., Coukos G. RNA interference, a potential strategy for isoform-specific phosphatydilinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biol Ther 2004; 3(12)1283–1289
   PubMed Web of Science ®Google Scholar